Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial

AIMS: Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation/atrial flutter (AF/AFL), it is im...

Descripción completa

Detalles Bibliográficos
Autores principales: Vamos, Mate, Oldgren, Jonas, Nam, Gi-Byoung, Lip, Gregory Y H, Calkins, Hugh, Zhu, Jun, Ueng, Kwo-Chang, Ludwigs, Ulf, Wieloch, Mattias, Stewart, John, Hohnloser, Stefan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175188/
https://www.ncbi.nlm.nih.gov/pubmed/34958366
http://dx.doi.org/10.1093/ehjcvp/pvab090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175188/
https://www.ncbi.nlm.nih.gov/pubmed/34958366
http://dx.doi.org/10.1093/ehjcvp/pvab090

Ejemplares similares